26, North St

Boston,

MA,

USA,

ZIP: 02109

Phone: +16174554188

The 2nd Genetic Vaccine Development for Infectious Diseases Summit (GVID) will reunite the vaccine community to learn from innovative biotechs, trailblazing large pharma, and pioneering academics as we focus on overcoming the pre-clinical and clinical translational challenges of developing genetic vaccines targeting infectious diseases. With a larger focus on respiratory infectious diseases, GVID provides an end-to-end detailed insight into the development of next-generation vaccine candidates for COVID-19 and beyond. 

This 3-day summit is built specifically for those looking to integrate novel vaccine development approaches into their pre-clinical studies through to clinical translation, covering mRNA, srRNA, pDNA, adenovirus, RV, and AAV-based vaccine platforms. Join 150+ senior decision makers from pre-clinical and clinical development, infectious diseases, virology, and R and D from the world's leading vaccine developers while accessing three ground-breaking days of content across two streams, 12+ hours of networking, and a focus day dedication to respiratory infections as we deliver the next era of vaccinology to prevent infectious diseases worldwide.

URLs:
Tickets: https://go.evvnt.com/1021307-2?pid=1052
Brochure: https://go.evvnt.com/1021307-3?pid=1052

Prices:
Drug Developer - Conference + Focus Day: USD 3997.00,
Drug Developer - Conference Only: USD 2999.00,
Solution Provider - Conference + Focus Day: USD 4797.00,
Solution Provider - Conference Only: USD 3599.00,
Academic - Conference + Focus Day: USD 3397.00,
Academic - Conference Only: USD 2599.00

Adam Crowe, Manager, Analytical Development, Precision Nanosystems, Afam Okoye, Research Associate Professor, VGTI-Vaccine and Gene Therapy Institute, OHSU, Aleš Štrancar, Chief Executive Officer, BIA Separations, Amesh Adalja, Senior Scholar, John Hopkins Centre for Health Security, Ami Patel, Research Assistant Professor, The WISTAR Institute, Andrew Geall, Chief Development Officer, Replicate Bio, Anna Blakney, Assistant Professor, University of British Columbia, Arun Kumar, Preclinical Vaccine Development Lead, CEPI, Birgitte Giersing, Technical Officer, Initiative for Vaccine Reseach, World Health Organisation, Bosco Paes, Professor Emeritus, Pediatrics, McMaster University, Cody Meissner, Chief, Division of Pediatric Infectious Disease; Professor of Pediatrics Tufts, University School of Medicine, Dan Barouch, William Bosworth Castle Professor of Medicine, Harvard Medical School, Danilo Casimiro, Vice President and Head, Global Research and External Innovation, Vaccine Platforms, Sanofi Pasteur, Denis Vargo, Vice President, Head of Drug Safety and Pharmacovigilance, Akebia Therapeutics, Dennis Christensen, Head of Vaccine Adjuvant Research, Statens Serum Institut, Don Diamond, Professor, Cancer and Viral Vaccines, City of Hope, Doug Holtzman, Chief Scientific Officer, ICOSAVAX, Dushyant Varshney, Chief Technology Officer, Arcturus Therapeutics, Emma Thompson, Professor of Infectious Diseases, Centre for Virus Research, University of Glasgow, Flor Munoz-Rivas, Pediatrics-Infectious Disease, Baylor College of Medicine, Galit Alter, Professor of Medicine, Harvard Medical School, Geeta Swamy, Associate Vice President for Research Vice Dean for Scientific Integrity Professor, Obstetrics and Gynecology, Duke University, Grace Chen, Senior Director, Clinical Development, Moderna, Hildegund Ertl, Professor, The WISTAR Institute, Ian Mitchell, Professor Emeritus, Department of Pediatrics, University of Calgary, Jakob Cramer, Head of Clinical Development, CEPI, Jesse Erasmus, Director of Virology, HDT Bio, Kate Broderick, Senior Vice President, R and D, INOVIO, Kavyon Modjarrad, Director, Emerging Infectious Diseases, Walter Reed Army Institute of Research, Kay Hunsberger, Director of Infrastructure for Biological Clinical Manufacturing, Merck, Leonard Krilov, Chairman, Department of Pediatrics, NYU Long Island School of Medicine, Luk Vandenberghe, Grousbeck Associate, Professor in Gene Therapy, Mass Eye and Ear Harvard Medical School, Martin Friede, Coordinator, Initiative for Vaccine Research, World Health Organisation, Michela Locci, Assistant Professor, Department of Microbiology, University of Pennsylvania, Richard Thwaites, Consultant Neonatologist, Portsmouth Hospital University, Sanie Sesay, Global Director Clinical Development, Vaccines, Sanofi Pasteur, Sean Sullivan, Executive Director, Arcturus Therapeutics, Vira Bitko, Vice President, Vaccine R and D, BlueWillow Biologics